RVMD · NASDAQ
Revolution Medicines (RVMD) Stock Price & Fundamentals
Revolution Medicines (RVMD) closed at $322.10 on Oct 9, 2026, down 0.35% from the previous close of $323.23.
Share price, past year
1Y +22.30%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $322.10 |
| Sep 30, 2026 | $318.59 |
| Aug 31, 2026 | $299.09 |
| Jul 31, 2026 | $312.83 |
| Jun 30, 2026 | $293.06 |
| May 29, 2026 | $277.97 |
| Apr 30, 2026 | $287.45 |
| Mar 31, 2026 | $298.25 |
| Feb 27, 2026 | $278.55 |
| Jan 30, 2026 | $277.69 |
| Dec 31, 2025 | $286.83 |
| Nov 28, 2025 | $274.77 |
| Oct 31, 2025 | $270.17 |
Key statistics
- Market cap
- $69.01B
- P/E (TTM)
- —
- EPS (TTM)
- −$8.86
- Revenue (TTM)
- —
- Net income (TTM)
- −$1.77B
- Shares outstanding
- 214.2M
- Dividend yield
- —
- 52-week range
- $258.80 – $328.31
Revolution Medicines's market cap is $69.01B, based on a share price of $322.10 and 214.2M shares outstanding as of Jun 30, 2026.
Financials
Revolution Medicines reported revenue of $0.00 for fiscal 2025.
Revolution Medicines reported a net loss of $1.13B in fiscal 2025.
Annual revenue
| Fiscal year | Revenue | Growth | Net income | Net margin | EPS (diluted) | Free cash flow |
|---|---|---|---|---|---|---|
| FY2025ended Dec 31, 2025 | $0.00 | — | −$1.13B | — | −$5.95 | −$913.73M |
| FY2024ended Dec 31, 2024 | $0.00 | −100.0% | −$600.09M | — | −$3.58 | −$567.74M |
| FY2023ended Dec 31, 2023 | $11.58M | −67.3% | −$436.37M | −3,768.3% | −$3.86 | −$358.30M |
| FY2022ended Dec 31, 2022 | $35.38M | +20.4% | −$248.71M | −703.0% | −$3.08 | −$235.22M |
| FY2021ended Dec 31, 2021 | $29.39M | −31.6% | −$187.09M | −636.6% | −$2.57 | −$153.71M |
| FY2020ended Dec 31, 2020 | $42.98M | −14.1% | −$108.16M | −251.6% | −$2.01 | −$103.00M |
| FY2019ended Dec 31, 2019 | $50.04M | +148.2% | −$47.66M | −95.3% | −$22.33 | −$52.21M |
| FY2018ended Dec 31, 2018 | $20.17M | — | −$41.79M | −207.2% | −$21.24 | −$286.00K |
| Quarter | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| Q4 FY2024ended Dec 31, 2024 | $0.00 | −$194.57M | −$1.13 |
| Q3 FY2024ended Sep 30, 2024 | $0.00 | −$156.29M | −$0.94 |
| Q2 FY2024ended Jun 30, 2024 | $0.00 | — | — |
| Q1 FY2024ended Mar 31, 2024 | $0.00 | — | — |
| Q4 FY2023ended Dec 31, 2023 | $742.00K | — | — |
| Q3 FY2023ended Sep 30, 2023 | $0.00 | — | — |
| Q2 FY2023ended Jun 30, 2023 | $3.82M | — | — |
| Q1 FY2023ended Mar 31, 2023 | $7.01M | — | — |
Company profile
- Name
- Revolution Medicines, Inc.
- Ticker
- RVMD
- Exchange
- NASDAQ
- Industry (SEC SIC)
- Biological Products, (No Diagnostic Substances)
- Headquarters
- 700 Saginaw Dr, Redwood City, CA 94063
- Incorporated in
- DE
- Fiscal year ends
- December
- SEC CIK
- 0001628171
Recent SEC filings
- Sep 1, 2026
- Aug 26, 2026
- Aug 5, 2026
- Aug 5, 2026
- Jun 22, 2026
- May 6, 2026
- May 6, 2026
- Apr 17, 2026
Frequently asked questions
What is Revolution Medicines's stock price?
Revolution Medicines (RVMD) closed at $322.10 on Oct 9, 2026, down 0.35% from the previous close of $323.23.
What is Revolution Medicines's market cap?
Revolution Medicines's market cap is $69.01B, based on a share price of $322.10 and 214.2M shares outstanding as of Jun 30, 2026.
How much revenue does Revolution Medicines make?
Revolution Medicines reported revenue of $0.00 for fiscal 2025.
Does Revolution Medicines pay a dividend?
Revolution Medicines's recent filings report no dividends declared over the last four quarters.
Sources and methodology
Fundamentals come from Revolution Medicines, Inc.'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures